Several abstracts and e-posters presented at ESC Congress 2026 and simultaneously published across the JACC family of journals highlight the expanding role of precision medicine, novel therapeutics, and advanced risk stratification across cardiovascular care.

JACC features investigations into genetically mediated LDL-C differences and venous thromboembolism risk, outcomes from the BRIGHT-4 trial looking at bivalirudin vs. heparin during primary PCI for STEMI, the clinical implications of low-normal hemoglobin in heart failure, and a VESALIUS-CV study analysis looking at the long-term benefits of evolocumab in high-risk patients without prior myocardial infarction or stroke.

JACC: Advances showcases a diverse portfolio of research addressing atrial cardiomyopathy, hypertrophic cardiomyopathy, ATTR amyloidosis, sex-specific cardiovascular outcomes, and cardiovascular genetics. Studies examine the impact of physical activity on atrial fibrillation risk, real-world outcomes associated with GLP-1 receptor agonists in hypertrophic cardiomyopathy with obstructive sleep apnea, cardiovascular risk among individuals without standard modifiable risk factors, and more.

JACC: Heart Failure focuses on emerging approaches to phenotype and risk-stratify heart failure populations, including investigations into transthyretin amyloid cardiomyopathy, myocardial histopathology-based heart failure classification, treatment effects in genotype-positive dilated cardiomyopathy, and a post-hoc analysis of the SOLOIST-WHF trial looking at benefits of sotagliflozin across a broad spectrum of baseline blood pressure levels.

JACC: Asia presents new insights into the DanGer Shock trial, reporting on eligibility, outcomes and health care costs associated with acute myocardial infarction in a Japanese nationwide cohort.

JACC: Cardiovascular Imaging features a secondary analysis of the HEARTS trial examining how cardiometabolic biomarkers relate to low-attenuation plaque progression in stable coronary artery disease.

JACC: Cardiovascular Interventions published research on patients receiving microaxial flow pump support, with a focus on the role of pre-implant angiography and vascular outcomes.

JACC: Basic to Translational Science advances mechanistic understanding of valvular heart disease through new research from the Valve-AS study exploring how SGLT2 inhibitors may influence molecular pathways involved in aortic valve remodeling in severe aortic stenosis.

JACC: Case Reports includes a clinical case on fulminant eosinophilic myocarditis in steroid-refractory hypereosinophilic syndrome.

Visit the JACC Journals at ESC Congress 2026 page to see the full list of simultaneous publications, information about editor-in-chief meet and greets, and more!

Clinical Topics: Arrhythmias and Clinical EP, Cardiovascular Care Team, Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Prevention, Pulmonary Hypertension and Venous Thromboembolism, Stable Ischemic Heart Disease, Valvular Heart Disease, Atherosclerotic Disease (CAD/PAD), Atrial Fibrillation/Supraventricular Arrhythmias, Lipid Metabolism, Nonstatins, Acute Heart Failure, Interventions and Coronary Artery Disease, Interventions and Imaging, Interventions and Structural Heart Disease, Interventions and Vascular Medicine, Angiography, Nuclear Imaging, Exercise, Sleep Apnea, Chronic Angina

Keywords: ESC Congress, ESC26, Aortic Valve, Atrial Fibrillation, Blood Pressure, Cholesterol, LDL, Coronary Artery Disease, Glucagon-Like Peptide-1 Receptor, Myocarditis, Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction, Sodium-Glucose Transporter 2 Inhibitors, Venous Thromboembolism, Cardiomyopathy, Hypertrophic, Hypertrophic Cardiomyopathy, Sleep Apnea, Obstructive, Exercise, Aortic Valve Stenosis, Heart Failure, Amyloidosis, Angiography, Stroke